mesalamine and Disease Exacerbation studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research Excerpts

Excerpt	Relevance	Reference
"Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients."	5.36	Mesalamine protects against colorectal cancer in inflammatory bowel disease. ( Pai, C; Sharif, O; Silverman, AL; Tang, J, 2010)
"Although oral mesalamine is the first-choice drug for treating mild-to-moderate ulcerative colitis (UC), some patients show symptoms of intolerance, including exacerbation of diarrhea and abdominal pain."	4.02	Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. ( Fujiwara, A; Higashi, R; Hiraoka, S; Inokuchi, T; Kato, J; Matsueda, K; Miyaike, J; Moritou, Y; Okada, H; Suzuki, S; Takagi, S; Takahara, M; Toyokawa, T, 2021)
" This new formulation with a reduced pill and dosing burden offers the potential to improve convenience and compliance in patients with active UC."	2.74	Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. ( Forbes, WP; Gordon, GL; Huang, S; Lamet, M; Mareya, S; Pruitt, R; Scherl, EJ; Shaw, A, 2009)
" With several medications (eg, sulfasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids, including budesonide) and complex dosing formulations, regimens, and routes, to treat a disease with variable anatomic extent, there is considerable practice variability in the management of patients with mild-moderate UC."	2.61	AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. ( Binion, DG; Feuerstein, JD; Singh, S; Tremaine, WJ, 2019)
"Conventional therapies for ulcerative colitis and Crohn's disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti-tumor necrosis factor agents."	2.47	Conventional medical management of inflammatory bowel disease. ( Burger, D; Travis, S, 2011)
"At least 1% of patients with Crohn's disease develop amyloidosis."	2.45	Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. ( Basturk, T; Kusaslan, R; Ozagari, A; Ozturk, T; Unsal, A, 2009)
"The management of luminal Crohn's disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease."	2.44	Mild-to-moderate active luminal Crohn's disease. ( Felley, C; Froehlich, F; Gonvers, JJ; Juillerat, P; Michetti, P; Mottet, C; Pittet, V; Vader, JP, 2007)
"Differentiating Crohn's disease (CD) from intestinal tuberculosis (TB) is a challenge."	1.62	Case of Crohn's Disease Initially Misdiagnosed as Intestinal Tuberculosis Due to Active Pulmonary Tuberculosis. ( Choi, S; Kim, D; Lee, T; Lim, W; Oh, H; Park, H; Park, S; Song, C; Yun, J, 2021)
"Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60)."	1.56	The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. ( Andersen, KW; Andersen, V; Arebi, N; Barros, L; Belousova, E; Bergemalm, D; Bortlik, M; Burisch, J; Christodoulou, DK; Collin, P; D'Incà, R; Dahlerup, JF; de Castro, L; Domislovic, V; Duricova, D; Ellul, P; Fumery, M; Gatt, K; Giannotta, M; Goldis, A; Gower-Rousseau, C; Halfvarson, J; Hernandez, V; Kaimakliotis, IP; Katsanos, KH; Kievit, HA; Kiudelis, G; Kjeldsen, J; Krznaric, Z; Kupčinskas, J; Lakatos, L; Lakatos, PL; Langholz, E; Magro, F; Midjord, JM; Misra, R; Munkholm, P; Nielsen, KR; Odes, S; Oksanen, P; Pedersen, N; Salupere, R; Sartini, A; Schwartz, D; Sebastian, S; Turcan, S; Valpiani, D, 2020)
"Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences."	1.48	ACG Clinical Guideline: Management of Crohn's Disease in Adults. ( Gerson, LB; Isaacs, KL; Lichtenstein, GR; Loftus, EV; Regueiro, MD; Sands, BE, 2018)
"There is no increased risk of tumors regarding the medications used."	1.48	Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior? ( Bosca-Watts, MM; Cortes, X; Gil, R; Hervás, D; Huguet, JM; Iborra, M; Maroto, N; Paredes, JM, 2018)
"Whether the epidemiology of ulcerative colitis (UC) has changed during recent decades is partly unknown."	1.46	Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. ( Cao, Y; Eriksson, C; Halfvarson, J; Henriksson, I; Montgomery, S; Rundquist, S; Zhulina, Y, 2017)
"Patients diagnosed with Crohn's disease including all age groups in the Uppsala healthcare region in the middle of Sweden 2005-2009 were included in the study."	1.46	Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009 ( Holmström, T; Karlbom, U; Rönnblom, A; Sjöberg, D; Tanghöj, H; Thörn, M, 2017)
"In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year."	1.46	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. ( Aicart, M; Alcaín, G; Almela, P; Arguelles-Arias, F; Arias-Rivera, ML; Barreiro-de Acosta, M; Barrio, J; Beltrán, B; Benítez, JM; Bermejo, F; Botella, B; Bujanda, L; Busquets, D; Calvet, X; Casanova, MJ; Castaño-Milla, C; Castro, E; Castro, L; Ceballos, D; Chaparro, M; Cortés, X; Domènech, E; Domínguez, M; Domínguez-Antonaya, M; Dueñas, C; Esteve, M; Fernández-Salazar, L; García-Herola, A; García-López, S; García-Planella, E; García-Sánchez, V; García-Sepulcre, MF; Garrido, E; Gisbert, JP; Gómez-García, M; Gomollón, F; González-Lama, Y; Guardiola, J; Gutiérrez, A; Hernández-Martínez, A; Hervías, D; Hinojosa, J; Huguet, JM; Jauregui-Amezaga, A; Khorrami, S; Leo, E; Llaó, J; Lorente-Poyatos, R; Mañosa, M; Marín-Jiménez, I; Marrero, JM; Martín-Arranz, M; Martinez-Montiel, MP; Menacho, M; Merino, O; Monfort, D; Moraleja, I; Muñoz, C; Muñoz, F; Nantes, O; Navarro-Llavat, M; Novella, MT; Opio, V; Pajares, R; Pérez-Calle, JL; Pérez-Martínez, I; Pineda, JR; Ponferrada, A; Ramírez-de la Piscina, P; Ramos, L; Robles-Alonso, V; Rodríguez, C; Rodríguez, GE; Rodríguez-Pérez, A; Rojas-Feria, M; Roncedo, O; Sánchez-Torres, A; Sicilia, B; Taxonera, C; Tosca, J; Van Domselaar, M; Vázquez, JM; Vega-López, AB, 2017)
"A man aged 56 years with a history of ulcerative colitis (UC) status postsubtotal colectomy was hospitalised with fevers, dry cough, eye redness and a new bloody, mucoid rectal discharge."	1.46	Subcorneal pustular dermatosis and episcleritis associated with poorly controlled ulcerative colitis. ( Adams, M; Trevino, J; Wargo, JJ, 2017)
"Although severe flare of ulcerative colitis (UC) is uncommon, it significantly increases the risk of preterm delivery, low birth weight and other adverse fetal outcomes."	1.46	Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem. ( Markovic, S; Protic, M; Tarabar, D, 2017)
"Elderly onset (>60 yrs at diagnosis) Crohn's disease (CD) seems to be associated with a better outcome than when diagnosed earlier in life."	1.43	Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study. ( Armengol Debeir, L; Charpentier, C; Coevoet, H; Dupas, JL; dʼAgay, L; Fumery, M; Gower-Rousseau, C; Pariente, B; Peyrin-Biroulet, L; Sarter, H; Savoye, G, 2016)
"Five years after diagnosis of ulcerative colitis, 5."	1.43	Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. ( Holmström, T; Karlbom, U; Rönnblom, A; Sjöberg, D; Tanghöj, H; Thörn, M, 2016)
"Prophylactic treatment of postoperative Crohn's disease (CD) plays a critical role in maintaining clinical remission."	1.43	Trends in Pharmacologic Interventions for Preventing Recurrence of Crohn's Disease After Ileocolonic Surgery. ( Grand, RJ; Mandl, KD; Ong, MS, 2016)
"Physicians traditionally treat ulcerative colitis (UC) using a step-up approach."	1.42	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. ( Fournier, N; Rogler, G; Safroneeva, E; Schoepfer, AM; Straumann, A; Vavricka, SR, 2015)
"Extraintestinal manifestations in Crohn's disease (CD) are frequent and well recognized."	1.42	Histologically confirmed case of cerebral vasculitis associated with Crohn's disease--a case report. ( Asaoka, K; Gekka, M; Kato, Y; Nishihara, H; Nomura, M; Sugiyama, T, 2015)
"Eosinophilic colitis is a rare mostly self-limiting disease affecting middle-aged adults."	1.40	Eosinophilic colitis is a sporadic self-limited disease of middle-aged people: a population-based study. ( Alfadda, AA; Shaffer, EA; Storr, MA; Urbanski, SJ, 2014)
"Although some ulcerative colitis (UC) patients are diagnosed when they do not have any UC-related symptoms, clinical features and prognosis of UC diagnosed in asymptomatic patients remain unclear."	1.40	Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. ( Byeon, JS; Jung, KW; Kim, J; Kim, JH; Kim, JW; Kim, KJ; Kim, SO; Myung, SJ; Park, SH; Park, SK; Yang, DH; Yang, SK; Ye, BD, 2014)
"Disease progression was monitored daily by observation of clinical signs and body weight change."	1.39	Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis. ( Che, X; Fan, HY; Liu, K; Lv, WH; Song, WW; Xu, H; Yang, MY; Zhang, ZL, 2013)
"Typical ulcerative colitis developed in five patients (25 %; four proctitis, one pancolitis) in a mean time of 18."	1.38	Long term follow-up of appendiceal and distal right-sided colonic inflammation. ( Byeon, JS; Jung, KW; Kim, JH; Kim, KJ; Kim, MJ; Myung, SJ; Park, SH; Yang, DH; Yang, SK; Ye, BD, 2012)
"Only one of them developed proximal disease progression."	1.37	Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice. ( Boix, J; Cabré, E; Domènech, E; Lorenzo-Zúñiga, V; Mañosa, M; Marín, L; Moreno, V; Naves, JE; Oller, B; Zabana, Y, 2011)
"Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients."	1.36	Mesalamine protects against colorectal cancer in inflammatory bowel disease. ( Pai, C; Sharif, O; Silverman, AL; Tang, J, 2010)
"Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)."	1.36	Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. ( Barrett, TA; Blatner, NR; Brown, JB; Cheresh, P; Dirisina, R; Goretsky, T; Grimm, GR; Khazaie, K; Lee, G; Li, L; Managlia, E; Yang, GY, 2010)
"Continued disease progression and relapse of UC over time are associated with an increased risk of colorectal cancer (CRC)."	1.34	Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. ( Boltri, JM; Tindall, WN; Wilhelm, SM, 2007)
"Prevention strategies for colorectal cancer in chronic ulcerative colitis (UC) are currently based on the identification of neoplasia by surveillance colonoscopy, but there is a great interest in the possibility of primary chemoprevention."	1.33	Will a 5-ASA a day keep the cancer (and dysplasia) away? ( Lashner, BA; Rubin, DT, 2005)
"Ursodeoxycholic acid (UDCA) treatment for primary sclerosing cholangitis (PSC) has been considered a rational therapy, though its effectiveness in the clinical course is still open to discussion."	1.31	Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis. ( Kikuchi, S; Kisara, N; Komatsu, K; Maruhama, Y; Shimosegawa, T; Toyota, T; Uchi, M; Ueno, Y, 2000)

Research

Studies (63)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Hospital Anxiety and Depression Score-Anxiety, (HADSA) at Week 13

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.17)	18.2507
2000's	17 (26.98)	29.6817
2010's	39 (61.90)	24.3611
2020's	5 (7.94)	2.80

Authors	Studies
Hiraoka, S	1
Fujiwara, A	1
Toyokawa, T	1
Higashi, R	1
Moritou, Y	1
Takagi, S	1
Matsueda, K	1
Suzuki, S	1
Miyaike, J	1
Inokuchi, T	1
Takahara, M	1
Kato, J	1
Okada, H	1
Burisch, J	2
Bergemalm, D	1
Halfvarson, J	3
Domislovic, V	1
Krznaric, Z	1
Goldis, A	2
Dahlerup, JF	1
Oksanen, P	2
Collin, P	2
de Castro, L	1
Hernandez, V	1
Turcan, S	2
Belousova, E	2
D'Incà, R	1
Sartini, A	1
Valpiani, D	2
Giannotta, M	1
Misra, R	2
Arebi, N	2
Duricova, D	2
Bortlik, M	2
Gatt, K	1
Ellul, P	2
Pedersen, N	3
Kjeldsen, J	2
Andersen, KW	2
Andersen, V	2
Katsanos, KH	2
Christodoulou, DK	2
Sebastian, S	2
Barros, L	2
Magro, F	2
Midjord, JM	1
Nielsen, KR	2
Salupere, R	2
Kievit, HA	1
Kiudelis, G	2
Kupčinskas, J	1
Fumery, M	3
Gower-Rousseau, C	3
Kaimakliotis, IP	2
Schwartz, D	2
Odes, S	2
Lakatos, L	1
Lakatos, PL	2
Langholz, E	2
Munkholm, P	2
Park, S	2
Lee, T	1
Lim, W	1
Park, H	1
Yun, J	1
Kim, D	1
Choi, S	1
Oh, H	1
Song, C	1
Yen, HH	1
Hsu, TC	1
Chen, MW	1
Su, PY	1
Chen, YY	1
Wan, J	1
Wang, X	1
Zhang, Y	1
Xue, X	1
Li, Y	1
Liu, Z	1
Han, S	1
Chen, M	1
Nie, Y	1
Shi, Y	1
Liang, J	1
Wu, K	1
Limdi, JK	1
Eriksson, C	2
Cao, Y	1
Rundquist, S	1
Zhulina, Y	1
Henriksson, I	1
Montgomery, S	1
Choi, YS	1
Kim, WJ	1
Kim, JK	1
Kim, DS	1
Lee, DH	1
Kato, S	1
Ishibashi, A	1
Kani, K	1
Yakabi, K	1
Lichtenstein, GR	1
Loftus, EV	1
Isaacs, KL	1
Regueiro, MD	1
Gerson, LB	1
Sands, BE	1
Huguet, JM	2
Iborra, M	1
Bosca-Watts, MM	1
Maroto, N	1
Gil, R	1
Cortes, X	2
Hervás, D	1
Paredes, JM	1
Schirmer, M	1
Denson, L	1
Vlamakis, H	1
Franzosa, EA	1
Thomas, S	1
Gotman, NM	1
Rufo, P	1
Baker, SS	1
Sauer, C	1
Markowitz, J	1
Pfefferkorn, M	1
Oliva-Hemker, M	1
Rosh, J	1
Otley, A	1
Boyle, B	1
Mack, D	1
Baldassano, R	1
Keljo, D	1
LeLeiko, N	1
Heyman, M	1
Griffiths, A	1
Patel, AS	1
Noe, J	1
Kugathasan, S	1
Walters, T	1
Huttenhower, C	1
Hyams, J	1
Xavier, RJ	1
Zammit, SC	1
Girardin, G	1
Brinar, M	1
Čuković-Čavka, S	1
Kievit, HAL	1
Myers, S	1
Midjord, J	1
Kupcinskas, L	1
Nikulina, I	1
Carmona, A	1
Pineda, JR	2
Vegh, Z	1
Singh, S	1
Feuerstein, JD	1
Binion, DG	1
Tremaine, WJ	1
Alfadda, AA	1
Shaffer, EA	1
Urbanski, SJ	1
Storr, MA	1
Fan, HY	1
Zhang, ZL	1
Liu, K	1
Yang, MY	1
Lv, WH	1
Che, X	1
Xu, H	1
Song, WW	1
Park, SK	1
Ye, BD	2
Yang, SK	2
Kim, SO	1
Kim, J	1
Kim, JW	1
Park, SH	2
Yang, DH	2
Jung, KW	2
Kim, KJ	2
Byeon, JS	2
Myung, SJ	2
Kim, JH	3
Chapuy, L	1
Bsat, M	1
Mehta, H	1
Rubio, M	1
Wakahara, K	1
Van, VQ	1
Baba, N	1
Cheong, C	1
Yun, TJ	1
Panzini, B	1
Wassef, R	1
Richard, C	1
Tamaz, R	1
Soucy, G	1
Delespesse, G	1
Sarfati, M	1
Safroneeva, E	1
Vavricka, SR	1
Fournier, N	1
Straumann, A	1
Rogler, G	1
Schoepfer, AM	1
Gekka, M	1
Sugiyama, T	1
Nomura, M	1
Kato, Y	1
Nishihara, H	1
Asaoka, K	1
Hawthrone, AB	1
Cheon, JH	2
Park, Y	1
Lee, HJ	1
Park, SJ	2
Kim, TI	2
Kim, WH	2
Gasparetto, M	1
Guariso, G	1
Pozza, LV	1
Ross, A	1
Heuschkel, R	1
Zilbauer, M	1
Knyazev, OV	1
Parfenov, AI	1
Konoplyannikov, AG	1
Boldyreva, ON	1
Pariente, B	1
Sarter, H	1
Charpentier, C	1
Armengol Debeir, L	1
Dupas, JL	1
Coevoet, H	1
Peyrin-Biroulet, L	1
dʼAgay, L	1
Savoye, G	1
Rönnblom, A	2
Holmström, T	2
Tanghöj, H	2
Karlbom, U	2
Thörn, M	2
Sjöberg, D	2
Ong, MS	1
Grand, RJ	1
Mandl, KD	1
Bodini, G	1
Giannini, EG	1
De Maria, C	1
Dulbecco, P	1
Furnari, M	1
Marabotto, E	1
Savarino, V	1
Savarino, E	1
Casanova, MJ	1
Chaparro, M	1
García-Sánchez, V	1
Nantes, O	1
Leo, E	1
Rojas-Feria, M	1
Jauregui-Amezaga, A	1
García-López, S	1
Arguelles-Arias, F	1
Aicart, M	1
Marín-Jiménez, I	1
Gómez-García, M	1
Muñoz, F	1
Esteve, M	1
Bujanda, L	1
Tosca, J	1
Mañosa, M	2
Llaó, J	1
Guardiola, J	1
Pérez-Martínez, I	1
Muñoz, C	2
González-Lama, Y	1
Hinojosa, J	1
Vázquez, JM	1
Martinez-Montiel, MP	1
Rodríguez, GE	1
Pajares, R	1
García-Sepulcre, MF	1
Hernández-Martínez, A	1
Pérez-Calle, JL	1
Beltrán, B	1
Busquets, D	1
Ramos, L	1
Bermejo, F	1
Barrio, J	1
Barreiro-de Acosta, M	1
Roncedo, O	1
Calvet, X	1
Hervías, D	1
Gomollón, F	1
Domínguez-Antonaya, M	1
Alcaín, G	1
Sicilia, B	1
Dueñas, C	1
Gutiérrez, A	1
Lorente-Poyatos, R	1
Domínguez, M	1
Khorrami, S	1
Taxonera, C	1
Rodríguez-Pérez, A	1
Ponferrada, A	1
Van Domselaar, M	1
Arias-Rivera, ML	1
Merino, O	1
Castro, E	1
Marrero, JM	1
Martín-Arranz, M	1
Botella, B	1
Fernández-Salazar, L	1
Monfort, D	1
Opio, V	1
García-Herola, A	1
Menacho, M	1
Ramírez-de la Piscina, P	1
Ceballos, D	1
Almela, P	1
Navarro-Llavat, M	1
Robles-Alonso, V	1
Vega-López, AB	1
Moraleja, I	1
Novella, MT	1
Castaño-Milla, C	1
Sánchez-Torres, A	1
Benítez, JM	1
Rodríguez, C	1
Castro, L	1
Garrido, E	1
Domènech, E	2
García-Planella, E	1
Gisbert, JP	1
Shimizu, H	1
Arai, K	1
Tang, J	2
Hosoi, K	1
Funayama, R	1
Wargo, JJ	1
Adams, M	1
Trevino, J	1
Protic, M	1
Markovic, S	1
Tarabar, D	1
Higgins, PD	1
Rubin, DT	2
Kaulback, K	1
Schoenfield, PS	1
Kane, SV	1
Freeman, HJ	1
Bousseaden, A	1
Ajana, FZ	1
Essamri, W	1
Benelbarhdadi, I	1
Afifi, R	1
Benazzouz, M	1
Essaid, A	1
Scherl, EJ	1
Pruitt, R	1
Gordon, GL	1
Lamet, M	1
Shaw, A	1
Huang, S	1
Mareya, S	1
Forbes, WP	1
Picco, MF	1
Zubiaurre, I	1
Adluni, M	1
Cangemi, JR	1
Shelton, D	1
Basturk, T	1
Ozagari, A	1
Ozturk, T	1
Kusaslan, R	1
Unsal, A	1
Sharif, O	1
Pai, C	1
Silverman, AL	1
Brown, JB	1
Lee, G	1
Managlia, E	1
Grimm, GR	1
Dirisina, R	1
Goretsky, T	1
Cheresh, P	1
Blatner, NR	1
Khazaie, K	1
Yang, GY	1
Li, L	1
Barrett, TA	1
Tomasello, G	1
Rodolico, V	1
Zerilli, M	1
Martorana, A	1
Bucchieri, F	1
Pitruzzella, A	1
Marino Gammazza, A	1
David, S	1
Rappa, F	1
Zummo, G	1
Damiani, P	1
Accomando, S	1
Rizzo, M	1
de Macario, EC	1
Macario, AJ	1
Cappello, F	1
Burger, D	1
Travis, S	1
Di Sabatino, A	1
Biancheri, P	1
Rovedatti, L	1
Macdonald, TT	1
Corazza, GR	1
Naves, JE	1
Lorenzo-Zúñiga, V	1
Marín, L	1
Oller, B	1
Moreno, V	1
Zabana, Y	1
Boix, J	1
Cabré, E	1
Munding, J	1
Ziebarth, W	1
Pox, CP	1
Ladigan, S	1
Reiser, M	1
Hüppe, D	1
Brand, L	1
Schmiegel, W	1
Tannapfel, A	1
Reinacher-Schick, AC	1
Kim, MJ	1
Kelly, S	1
Jung, YS	1
Hong, SP	1
Aqel, B	1
Bishop, M	1
Krishna, M	1
Cangemi, J	1
Velayos, FS	1
Terdiman, JP	1
Walsh, JM	1
Lashner, BA	1
Roberta, P	1
Antonino, B	1
Paolo, P	1
Fägerstam, JP	1
Whiss, PA	1
García-Morán, S	1
Sáez-Royuela, F	1
Pérez-Alvarez, JC	1
Gento, E	1
Téllez, J	1
Di Mario, F	1
Comparato, G	1
Fanigliulo, L	1
Aragona, G	1
Cavallaro, LG	1
Cavestro, GM	1
Franzé, A	1
Nandi, J	1
Saud, B	1
Zinkievich, JM	1
Palma, DT	1
Levine, RA	1
Tindall, WN	1
Boltri, JM	1
Wilhelm, SM	1
Michetti, P	1
Juillerat, P	1
Mottet, C	1
Pittet, V	1
Gonvers, JJ	1
Vader, JP	1
Froehlich, F	1
Felley, C	1
Keljo, DJ	1
Sugerman, KS	1
Peppercorn, MA	1
Komatsu, K	1
Shimosegawa, T	1
Kikuchi, S	1
Uchi, M	1
Maruhama, Y	1
Kisara, N	1
Ueno, Y	1
Toyota, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.[NCT04165265]		28 participants (Anticipated)	Interventional	2019-12-03	Recruiting
"A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2023-10-11	Recruiting
Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation[NCT02994836]	Phase 4	139 participants (Actual)	Interventional	2017-04-21	Completed
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)[NCT04576000]		3 participants (Actual)	Observational	2020-08-25	Terminated (stopped due to Not able to meet recruitment targets)
"Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)"[NCT02077777]	Phase 2	21 participants (Actual)	Interventional	2012-10-31	Completed
Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163]		26 participants (Actual)	Interventional	2007-10-31	Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks

Hospital Anxiety and Depression Score-Depression (HADSD)

Intervention	score on a scale (Median)
UC Patients Given Gut-focussed Hpynotherapy	7
UC Patients Given Control Educational Sessions	10

Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks

Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 13

Intervention	units on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy	1.5
UC Patients Given Control Educational Sessions	4

IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks

Perceived Stress Questionnaire-Recent (PSQ-R)

Intervention	units on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy	195
UC Patients Given Control Educational Sessions	192

Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks

Relapse at 1 Year

Intervention	units on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy	0.3
UC Patients Given Control Educational Sessions	0.4

The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year

Article	Year
Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. Digestion, 2018, Volume: 97, Issue:1 Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Consensus; Di	2018
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology, 2019, Volume: 156, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Management; Disease Pro	2019
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Alimentary pharmacology & therapeutics, 2009, Feb-01, Volume: 29, Issue:3 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cost-Benefit Analys	2009
Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. Journal of renal care, 2009, Volume: 35, Issue:3 Topics: Adult; Amyloidosis; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colchicine; Crohn Disease; Dise	2009
Conventional medical management of inflammatory bowel disease. Gastroenterology, 2011, Volume: 140, Issue:6 Topics: Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroid	2011
Recent advances in understanding ulcerative colitis. Internal and emergency medicine, 2012, Volume: 7, Issue:2 Topics: Biopsy, Needle; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms; Combined Modality Therapy; Dis	2012
Collagenous colitis evolving into ulcerative colitis: a case report and review of the literature. Digestive diseases and sciences, 2003, Volume: 48, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colitis, Ulcerative; Colonoscopy; Diagnosis, Diffe	2003
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. The American journal of gastroenterology, 2005, Volume: 100, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color	2005
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. The American journal of gastroenterology, 2005, Volume: 100, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color	2005
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. The American journal of gastroenterology, 2005, Volume: 100, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color	2005
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. The American journal of gastroenterology, 2005, Volume: 100, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color	2005
Use of mesalazine in diverticular disease. Journal of clinical gastroenterology, 2006, Volume: 40 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Disease Progression; Diverticulitis, Colonic; Di	2006
Mild-to-moderate active luminal Crohn's disease. Digestion, 2007, Volume: 76, Issue:2 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disea	2007

Article	Year
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:1 Topics: Abdominal Pain; Administration, Oral; Adult; Colitis, Ulcerative; Diarrhea; Disease Progression; Fem	2021
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. United European gastroenterology journal, 2020, Volume: 8, Issue:8 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Colectomy; Crohn Disease; Diseas	2020
Case of Crohn's Disease Initially Misdiagnosed as Intestinal Tuberculosis Due to Active Pulmonary Tuberculosis. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2021, 01-25, Volume: 77, Issue:1 Topics: Adolescent; Anti-Inflammatory Agents; Antitubercular Agents; Colonoscopy; Crohn Disease; Diagnostic	2021
Clinical features and treatment of inflammatory bowel disease in a low-incidence area: A hospital-based retrospective cohort study in Taiwan. Medicine, 2021, Mar-12, Volume: 100, Issue:10 Topics: Adult; Age Factors; Biological Factors; Colectomy; Colitis, Ulcerative; Crohn Disease; Databases, Fa	2021
5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study. Canadian journal of gastroenterology & hepatology, 2021, Volume: 2021 Topics: Colon; Crohn Disease; Disease Progression; Humans; Mesalamine; Retrospective Studies	2021
Aminosalicylates and Elderly-onset Colonic Crohn's Disease-More Than Meets the Eye? Journal of Crohn's & colitis, 2017, Aug-01, Volume: 11, Issue:8 Topics: Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Disease Progression; Humans; M	2017
Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:8 Topics: Adolescent; Adult; Cohort Studies; Colectomy; Colitis, Ulcerative; Disease Progression; Female; Huma	2017
Efficacy of topical 5-aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation. Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:6 Topics: Administration, Ophthalmic; Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Ant	2018
ACG Clinical Guideline: Management of Crohn's Disease in Adults. The American journal of gastroenterology, 2018, Volume: 113, Issue:4 Topics: Adalimumab; Adrenal Cortex Hormones; Antibodies, Monoclonal; Certolizumab Pegol; Crohn Disease; Dise	2018
Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior? Scandinavian journal of gastroenterology, 2018, Volume: 53, Issue:9 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Comorbidity; Cross-Sectional Studies; Disease Prog	2018
Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell host & microbe, 2018, 10-10, Volume: 24, Issue:4 Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschoo	2018
Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:6 Topics: Adult; Cohort Studies; Colectomy; Colitis, Ulcerative; Disease Progression; Europe; Female; Follow-U	2019
Eosinophilic colitis is a sporadic self-limited disease of middle-aged people: a population-based study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2014, Volume: 16, Issue:2 Topics: Abdominal Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis; Colon	2014
Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis. World journal of gastroenterology, 2013, Dec-28, Volume: 19, Issue:48 Topics: Animals; Anti-Inflammatory Agents; Boraginaceae; Colitis, Ulcerative; Colon; Disease Models, Animal;	2013
Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. Journal of Crohn's & colitis, 2014, Volume: 8, Issue:10 Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Diseases	2014
Basophils increase in Crohn disease and ulcerative colitis and favor mesenteric lymph node memory TH17/TH1 response. The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Basophils; Cell Movement; Cell Proliferation; Cell Survival	2014
Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflammatory bowel diseases, 2015, Volume: 21, Issue:6 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S	2015
Histologically confirmed case of cerebral vasculitis associated with Crohn's disease--a case report. BMC neurology, 2015, Sep-21, Volume: 15 Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy;	2015
Editorial: preventing disease progression in Crohn's--can we shut the stable door before the horse bolts? Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:9 Topics: Animals; Azathioprine; Crohn Disease; Disease Progression; Humans; Immunologic Factors; Mesalamine;	2015
EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS. Danish medical journal, 2015, Volume: 62, Issue:12 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Denmark; Diet Th	2015
Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C	2016
Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC gastroenterology, 2016, Mar-15, Volume: 16 Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Age of Onset; Anti-Bacterial Agents; Anti-Inflammat	2016
[Use of mesenchymal stem cells in the combination therapy of ulcerative colitis]. Terapevticheskii arkhiv, 2016, Volume: 88, Issue:2 Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Colonoscopy; Combined Modality Therapy; Diseas	2016
Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study. Inflammatory bowel diseases, 2016, Volume: 22, Issue:7 Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Col	2016
Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Colectomy; Colitis, Ulcerative; Disease Progression; Female; Humans;	2016
Trends in Pharmacologic Interventions for Preventing Recurrence of Crohn's Disease After Ileocolonic Surgery. Inflammatory bowel diseases, 2016, Volume: 22, Issue:10 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Colectomy; Colon; Crohn Disease;	2016
Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009 Scandinavian journal of gastroenterology, 2017, Volume: 52, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites; Child; Colonoscopy; Crohn Disease; Dise	2017
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:2 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Disease; Dise	2017
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. The American journal of gastroenterology, 2017, Volume: 112, Issue:1 Topics: Adalimumab; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Colitis,	2017
5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis. Pediatrics international : official journal of the Japan Pediatric Society, 2017, Volume: 59, Issue:5 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Disease Progression	2017
Subcorneal pustular dermatosis and episcleritis associated with poorly controlled ulcerative colitis. BMJ case reports, 2017, Jan-30, Volume: 2017 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Disease Progression; Enema;	2017
Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem. Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:1-2 Topics: Adrenal Cortex Hormones; Adult; Colitis, Ulcerative; Disease Progression; Female; Humans; Infliximab	2017
Segmental colitis associated with diverticulosis syndrome. World journal of gastroenterology, 2008, Nov-14, Volume: 14, Issue:42 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Diagnosis, Differential; Disease Progression; Dive	2008
Mesalamine enema-induced exacerbation of ulcerative colitis. International journal of colorectal disease, 2009, Volume: 24, Issue:11 Topics: Adult; Colitis, Ulcerative; Disease Progression; Enema; Female; Humans; Mesalamine	2009
Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. The American journal of gastroenterology, 2009, Volume: 104, Issue:11 Topics: Adrenal Cortex Hormones; Adult; Cohort Studies; Confidence Intervals; Crohn Disease; Digestive Syste	2009
Mesalamine protects against colorectal cancer in inflammatory bowel disease. Digestive diseases and sciences, 2010, Volume: 55, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Case-Control Studies; Chi-S	2010
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology, 2010, Volume: 138, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Biopsy; Cell Proliferation; Colitis,	2010
Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice. Journal of gastrointestinal and liver diseases : JGLD, 2011, Volume: 20, Issue:4 Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory	2011
The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway. Carcinogenesis, 2012, Volume: 33, Issue:3 Topics: Adenoma; beta Catenin; Cadherins; Cell Line, Tumor; Colitis, Ulcerative; Colorectal Neoplasms; Cycli	2012
Long term follow-up of appendiceal and distal right-sided colonic inflammation. Endoscopy, 2012, Volume: 44, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Appendicitis; Colitis, Ulcerative; Colonoscopy; Dise	2012
Ulcerative colitis. BMJ (Clinical research ed.), 2012, May-10, Volume: 344 Topics: Anecdotes as Topic; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis, Ulcerative; D	2012
Clinical course of intestinal Behcet's disease during the first five years. Digestive diseases and sciences, 2013, Volume: 58, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Disease Pr	2013
Will a 5-ASA a day keep the cancer (and dysplasia) away? The American journal of gastroenterology, 2005, Volume: 100, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Disease Progress	2005
Inflammatory bowel disease and drug intake. Inflammatory bowel diseases, 2005, Volume: 11, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Inflammatory Bowel Dis	2005
Higher platelet P-selectin in male patients with inflammatory bowel disease compared to healthy males. World journal of gastroenterology, 2006, Feb-28, Volume: 12, Issue:8 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Colitis, Ulcerative; Crohn Di	2006
Myopericarditis and mitral insufficiency associated with ulcerative colitis treated with mesalazine. Inflammatory bowel diseases, 2006, Volume: 12, Issue:4 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Progression; Humans; Ma	2006
5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Digestive diseases and sciences, 2008, Volume: 53, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Blotting, Western; Cyclooxygenase Inhi	2008
Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. Journal of managed care pharmacy : JMCP, 2007, Volume: 13, Issue:7 Suppl A Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Controlled Clini	2007
Pancreatitis in patients with inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition, 1997, Volume: 25, Issue:1 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Azathioprine;	1997
A 66-year-old woman with ulcerative colitis. JAMA, 1998, Mar-25, Volume: 279, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Decision Making; Diagnosis, Diff	1998
Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis. Internal medicine (Tokyo, Japan), 2000, Volume: 39, Issue:12 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Autoimmune Diseases; Betame	2000

mesalamine and Disease Exacerbation